openPR Logo
Press release

Neuropathic Pain Market is Projected to Hit US$ 14,538.7 Million at a 5.7% CAGR by 2034

02-19-2024 02:18 AM CET | Health & Medicine

Press release from: Fact.MR

Neuropathic Pain Market

Neuropathic Pain Market

The neuropathic pain sector in North America boasts a valuation of US$ 3,295 million in 2024. Combinations of various treatments are highly favored among patients in this region, allowing physicians to develop medications that effectively target multiple pain circuits simultaneously.

The neuropathic pain market was valued at approximately US$ 6,316.6 million in 2019. The combined worth of neuropathic drugs and nerve pain relief services is projected to reach US$ 8,382.9 million in 2024. The global demand for medications and services aimed at alleviating neuropathic pain is expected to experience a steady Compound Annual Growth Rate (CAGR) of 5.7% through 2034. By 2034, the industry is anticipated to reach a substantial value of US$ 14,538.7 million.

๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐š ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‚๐จ๐ฉ๐ฒ ๐จ๐Ÿ ๐“๐ก๐ข๐ฌ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9614

Neuropathic pain, a debilitating condition arising from damage or dysfunction of the nervous system, has long been a challenge for both patients and healthcare providers. However, recent advancements and emerging trends in treatment options are reshaping the landscape of the neuropathic pain market.

Rising Prevalence and Awareness:

One of the primary factors propelling the neuropathic pain market to prominence is the increasing prevalence of neuropathic pain conditions worldwide. Conditions such as diabetic neuropathy, postherpetic neuralgia, and neuropathic pain associated with spinal cord injuries are becoming more prevalent, driving the demand for effective treatments. Additionally, heightened awareness among healthcare professionals and patients about the impact of neuropathic pain on quality of life is leading to earlier diagnosis and intervention.

Advancements in Treatment Modalities:

In recent years, significant advancements have been made in the development of novel treatment modalities for neuropathic pain. Traditional therapies such as anticonvulsants, antidepressants, and opioids have limitations in terms of efficacy and tolerability. However, emerging therapies, including topical medications, gene therapy, and neuromodulation techniques such as spinal cord stimulation and peripheral nerve stimulation, offer new hope for patients with neuropathic pain. These innovative approaches target the underlying mechanisms of neuropathic pain, providing more targeted and effective relief.

Personalized Medicine and Precision Therapeutics:

Another trend shaping the neuropathic pain market is the shift towards personalized medicine and precision therapeutics. Advances in genetic testing, biomarker identification, and pharmacogenomics are enabling healthcare providers to tailor treatment approaches to individual patients based on their unique genetic makeup, disease characteristics, and treatment response. By adopting a personalized approach to neuropathic pain management, clinicians can optimize treatment outcomes and minimize adverse effects, ultimately improving patient satisfaction and quality of life.

๐‘๐ž๐š๐ ๐Œ๐จ๐ซ๐ž:https://www.factmr.com/report/neuropathic-pain-market

๐‚๐จ๐ฆ๐ฉ๐ž๐ญ๐ข๐ญ๐ข๐ฏ๐ž ๐‹๐š๐ง๐๐ฌ๐œ๐š๐ฉ๐ž:

Major players in the neuropathic pain market comprise Pfizer Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Sanofi S.A, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., and Baxter International Inc.

These industry leaders have solidified their positions through strategic partnerships with healthcare organizations, enhancing the legitimacy and accessibility of neuropathic pain medications. By adhering rigorously to healthcare regulations, they have garnered substantial market share. Moreover, government initiatives aimed at managing chronic pain have paved the way for the emergence of numerous neuropathic pain remedy providers.

Recent Developments

In September 2022, AlgoTx Corporation initiated a phase 2 clinical trial to evaluate ATX01 for chemotherapy-induced peripheral neuropathy (CIPN) sufferers. This groundbreaking medication, topical amitriptyline, underwent clinical trials across more than 40 locations in Europe and the United States.

In January 2020, researchers at Huazhong Agricultural University in China uncovered that Synaptotagmin 1 (Syt-1), a synaptic vesicle protein, could prevent neuropathic pain. Their findings suggest that electroacupuncture suppresses spinal Syt-1, thereby alleviating neuropathic pain. This breakthrough, along with numerous other studies, underscores the efficacy of electroacupuncture in managing neuropathic pain.

๐Š๐ž๐ฒ ๐’๐ž๐ ๐ฆ๐ž๐ง๐ญ๐ฌ ๐‚๐จ๐ฏ๐ž๐ซ๐ž๐ ๐›๐ฒ ๐๐ž๐ฎ๐ซ๐จ๐ฉ๐š๐ญ๐ก๐ข๐œ ๐๐š๐ข๐ง ๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐’๐ฎ๐ซ๐ฏ๐ž๐ฒ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ

By Drug Class :
Tricyclic Anti-Depressants
Anticonvulsants
SNRI's
Capsaicin Cream
Local Anesthesia
Opioids
Steroids
Other Drugs

By Indication Type :
Diabetic Neuropathy
Trigeminal Neuralgia
Post-Herpetic Neuralgia
Chemotherapy-Induced Peripheral Neuropathy
Other Indications

By Sales/Distribution Channel :
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Other Sales Channels

By Region :
North America Market
Europe Market
Latin America Market
East Asia Market
South Asia & Oceania Market
Middle East & Africa (MEA) Market

As the burden of neuropathic pain continues to grow, fueled by demographic trends and the increasing prevalence of chronic diseases, the demand for effective and personalized treatment options is on the rise. Emerging trends such as advancements in treatment modalities, personalized medicine, non-pharmacological interventions, and expanded research efforts are driving the neuropathic pain market to prominence. By harnessing these trends and embracing a multidisciplinary approach to pain management, stakeholders can enhance patient outcomes and improve the quality of life for millions of individuals living with neuropathic pain.

๐“๐จ๐ฉ ๐‘๐ž๐ฅ๐š๐ญ๐ž๐ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐ข๐ง ๐ญ๐ก๐ž ๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ

Ischemic Optic Neuropathy Treatment Market
https://www.factmr.com/report/ischemic-optic-neuropathy-treatment-market
Diabetic Neuropathy Market
https://www.factmr.com/report/4698/diabetic-neuropathy-market
Neuroprotection Therapeutics Market
https://www.factmr.com/report/neuroprotection-therapeutics-market

๐‚๐จ๐ง๐ญ๐š๐œ๐ญ:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

๐€๐›๐จ๐ฎ๐ญ ๐…๐š๐œ๐ญ.๐Œ๐‘

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neuropathic Pain Market is Projected to Hit US$ 14,538.7 Million at a 5.7% CAGR by 2034 here

News-ID: 3388536 • Views: โ€ฆ

More Releases from Fact.MR

Bioinformatics Market is Growing at a CAGR of 13.4% by 2034 | Fact.MR Report
Bioinformatics Market is Growing at a CAGR of 13.4% by 2034 | Fact.MR Report
The latest report on the Bioinformatics Market, projecting robust growth driven by the increasing demand for genomic research, advancements in artificial intelligence (AI), and the rising adoption of precision medicine. Valued at USD 14.29 billion in 2024, the global market is forecast to expand at a compound annual growth rate (CAGR) of 13.4%, reaching USD 50.25 billion by 2034. This significant growth underscores the critical role of bioinformatics in decodingโ€ฆ
Residential Robotic Vacuum Cleaner Market to Reach USD 11.6 Billion by 2033 | Key Players: iRobot Corporation, Neato Robotics, Inc., Yujin Robot, Co., Ltd., and Dyson Inc
Residential Robotic Vacuum Cleaner Market to Reach USD 11.6 Billion by 2033 | Ke โ€ฆ
Fact.MR today released its latest report on the Residential Robotic Vacuum Cleaner Market, projecting robust growth driven by increasing demand for automation, busy lifestyles, and advancements in smart home technologies. Valued at USD 3.0 billion in 2023, the global market is forecast to expand at a compound annual growth rate (CAGR) of 14.4%, reaching USD 11.6 billion by 2033. This significant growth highlights the rising adoption of robotic vacuum cleanersโ€ฆ
Brain-Computer Interface Market is Estimated to Reach USD 6.5 Billion by 2033
08-29-2025 | Health & Medicine
Fact.MR
Brain-Computer Interface Market is Estimated to Reach USD 6.5 Billion by 2033
The global brain-computer interface (BCI) market was valued at USD 1.6 billion in 2022 and is projected to reach USD 6.5 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.6% from 2023 to 2033. This expansion reflects the increasing adoption of BCI technologies in medical applications, driven by advancements in neuroscience, AI, and sensor technologies. BCIs enable direct communication between the brain and external devices, offeringโ€ฆ
Orally Disintegrating Tablet Market is Projected to Reach USD 72.68 Billion by 2034 | Key Players: Johnson & Johnson Services Inc; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited
08-29-2025 | Health & Medicine
Fact.MR
Orally Disintegrating Tablet Market is Projected to Reach USD 72.68 Billion by 2 โ€ฆ
The global orally disintegrating tablet (ODT) market is valued at USD 24.45 billion in 2024 and is forecasted to expand at a compound annual growth rate (CAGR) of 11.5%, reaching USD 72.68 billion by 2034. This robust growth is driven by the increasing demand for patient-friendly dosage forms, particularly among the elderly, pediatric, and dysphagic populations, who benefit from ODTs' ease of administration without water and rapid dissolution. ODTs enhanceโ€ฆ

All 5 Releases


More Releases for Neuropathic

Neuropathic Pain Management Market Size Analysis by Application, Type, and Regio โ€ฆ
USA, New Jersey- According to Market Research Intellect, the global Neuropathic Pain Management market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period. The neuropathic pain management market is experiencing consistent growth due to rising incidences of chronic conditions such as diabetes, cancer, and neurological disorders, whichโ€ฆ
Neuropathic Pain Market New Therapeutic Developments and Treatments
On April 08, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Neuropathic Pain Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands acrossโ€ฆ
Neuropathic Pain Market: Innovative Therapies Reshaping Chronic Pain Management
In recent years, the global Neuropathic Pain Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Neuropathic Pain Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices includingโ€ฆ
The increase in Neuropathic Ocular Pain Market Size is a direct consequence of i โ€ฆ
As per DelveInsight, the Neuropathic Ocular Pain Market is anticipated to grow in the coming years owing to the rise in the number of prevalent cases in the 7MM, the improvement in the research and development activities, and the launch of novel therapies in the Neuropathic Ocular Pain market. There are several key players involved in developing therapies for Neuropathic Ocular Pain, like Novartis, and others. The Neuropathic Ocular Pain marketโ€ฆ
Neuropathic Pain Market Growth Factors and Manufacturers
Neuropathic Pain Market 2022 Global Neuropathic Pain Market to Reach US$ 8.3 Bn by 2024 End. Machine learning and artificial intelligence have been transforming the healthcare vertical since the last few years. AI-powered healthcare solutions are there to help the patients with automation of routine tasks and data analysis. Wearable technologies are a part of exclusive physiotherapy devices that are capable of tracking and analyzing specific movements of the patients. This wouldโ€ฆ
Global Neuropathic Pain Market Research Report Forecast to 2023
Neuropathic Pain Market 2020 comprises a detailed survey of the Neuropathic Pain Market size, share, trends, extension, consumption, and share, segments, application and Forecast 2025. Global "Neuropathic Pain" Market 2020-2025 Report contains all demographic as well as analytical data regarding market review, growth, demand, and budget analysis. The report mainly highlights the significant trends of the Neuropathic Pain market in terms of thriving companies, business methods, product values and pricing, revenue,โ€ฆ